Corneal Toxicity in Patients Receiving Antibody–Drug Conjugates for the Treatment of Cancer

Corneal Toxicity in Patients Receiving Antibody–Drug Conjugates for the Treatment of Cancer

Friday, November 12, 2021
Webinar -- 7:00 PM CT
https://www.clinicaloptions.com/ocularAE2021Join1

Agenda

Welcome and Introduction
Overview of Ocular Toxicity Associated with Antibody Drug Conjugates
Clinical Case Study: BCMA-Targeted Antibody Drug Conjugate in MM
Panel Discussion and Audience Question and Answer Session
Managing ADC-Associated Ocular Toxicity in Patients with Cancer
Panel Discussion and Audience Question and Answer Session
Final Thoughts

Faculty

Faculty
Asim V. Farooq, MD

Associate Professor of Ophthalmology
Vice Chair of Academic Affairs
Department of Ophthalmology and Visual Science
University of Chicago Medical Center
Chicago, Illinois

Faculty
Joann Kang, MD

Associate Professor of Ophthalmology
Montefiore Medical Center/Albert Einstein College of Medicine
Director, Cornea and Refractive Surgery
Montefiore Medical Center
Bronx, New York

Faculty
Paul G. Richardson, MD

R. J. Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader
Director of Clinical Research

Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in the mitigation and management of ocular toxicity for patients with cancer who are receiving antibody–drug conjugates.

Target Audience
This educational program is intended for ophthalmologists, optometrists, medical oncologists, and other healthcare professionals who provide care for patients receiving antibody–drug conjugates for the treatment of cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply the available data and expert recommendations to optimally monitor for ocular toxicity in patients with cancer who are receiving antibody–drug conjugates
  • Plan appropriate therapeutic interventions with treating hematologists and oncologists in patients experiencing ocular toxicities from antibody–drug conjugate therapy to maximize clinical outcomes from anticancer therapy and mitigate worsening keratopathy
  • Describe the pathophysiology of corneal toxicity associated with antibody–drug conjugates

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.